Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin

Journal of Viral Hepatitis

Volumn 20, Issue 4, 2013, Pages

  Foster, G R ^a   Zeuzem, S ^b   Pianko, S ^c   Sarin, S K ^d   Piratvisuth, T ^e   Shah, S ^f   Andreone, P ^g   Sood, A ^h   Chuang, W L ⁱ   Lee, C M ^j   George, J ^k   Gould, M ^l   Flisiak, R ^m   Jacobson, I M ⁿ   Komolmit, P ^o   Thongsawat, S ^p   Tanwandee, T ^q   Rasenack, J ^r   Sola, R ^s   Messina, I ^t   Yin, Y ^t   Cammarata, S ^t   Feutren, G ^t   Brown, K K ^u   more..

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c MONASH MEDICAL CENTRE   (Australia)

^d G B PANT HOSPITAL   (India)

^e PRINCE OF SONGKLA UNIVERSITY   (Thailand)

^f JASLOK HOSPITAL AND RESEARCH CENTRE   (India)

^g UNIVERSITY OF BOLOGNA   (Italy)

^h DAYANAND MEDICAL COLLEGE AND HOSPITAL   (India)

ⁱ KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^j CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^k UNIVERSITY OF SYDNEY   (Australia)

^l Toronto Digestive Disease Associates   (Canada)

^m Wojewódzki Szpital Specjalistyczny im D uskiego   (Poland)

ⁿ NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^o KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

^p CHIANG MAI UNIVERSITY   (Thailand)

^q MAHIDOL UNIVERSITY   (Thailand)

^r UNIVERSITY OF FREIBURG   (Germany)

^s HOSPITAL DEL MAR   (Spain)

^t NOVARTIS PHARMA AG   (Switzerland)

^u DEPARTMENT OF MEDICINE   (United States)

more..

Author keywords

albinterferon alfa 2b; hepatitis C virus; interferon; interstitial lung disease; pegylated interferon; pulmonary function

Indexed keywords

ALPHA INTERFERON; CARBON MONOXIDE; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; COUGHING; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EXPIRATORY RESERVE VOLUME; FEMALE; FORCED VITAL CAPACITY; GENOTYPE; HEPATITIS C; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG DIFFUSION CAPACITY; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPIROMETRY; THORAX RADIOGRAPHY; TREATMENT DURATION;

ADULT; ALBUMINS; ANTIVIRAL AGENTS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LUNG; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PULMONARY DIFFUSING CAPACITY; RADIOGRAPHY, THORACIC; RECOMBINANT PROTEINS; RIBAVIRIN; SPIROMETRY;

EID: 84875216158     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12020     Document Type: Article

References (18)

1. Ghany MG, Strader DB, Thomas DL, Seeff LB, for the American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374.
2. Slavenburg S, Heijdra YF, Drenth JP,. Pneumonitis as a consequence of (peg)interferon-ribavirin combination therapy for hepatitis C: a review of the literature. Dig Dis Sci 2010; 55: 579-585.
3. Arase Y, Suzuki F, Suzuki Y, et al,. Hepatitis C virus enhances incidence of idiopathic pulmonary fibrosis. World J Gastroenterol 2008; 14: 5880-5886.
4. Subramanian GM, Fiscella M, Lamousé-Smith A, Zeuzem S, McHutchison JG, Albinterferon α-2b: a genetic fusion protein for the treatment of chronic hepatitis C. Nat Biotechnol 2007; 25: 1411-1419.
5. Nelson DR, Benhamou Y, Chuang WL, et al. for ACHIEVE-2/3 Study Team. Albinterferon alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3. Gastroenterology 2010; 139: 1267-1276.
6. Zeuzem S, Sulkowski MS, Lawitz EJ, et al,; for ACHIEVE-1 Study Team. Albinterferon alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1. Gastroenterology 2010; 139: 1257-1266.
7. Pianko S, Zeuzem S, Chuang WL, et al,. Randomized trial of albinterferon-alfa-2b every four weeks for genotype 2/3 chronic hepatitis C. J Viral Hepat 2012; 19: 623-634.
8. MacIntyre N, Crapo RO, Viegi G, et al,. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 2005; 26: 720-735.
9. Miller R, Hankinson J, Brusasco V, et al,. Standardization of spirometry. Eur Respir J 2005; 26: 319-338.
10. Noble PW, Albera C, Bradford WZ, et al,; CAPACITY Study Group. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377: 1760-1769.
11. Raghu G, Collard HR, Egan JJ, et al,; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824.
12. Division of Microbiology and Infectious Diseases Adult Toxicity Tables. Available at: www.niaid.nih.gov/LabsAndResources/resources/DMIDClinRsrch/pages/ toxtables.aspx. (accessed 2 February 2011).
13. Hankinson JL, Odencrantz JR, Fedan KB,. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999; 159: 179-187.
14. Pellegrino R, Viegi G, Brusasco V, et al,. Interpretative strategies for lung function tests. Eur Respir J 2005; 26: 948-968.
15. Ge D, Fellay J, Thompson AJ, et al,. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
16. Moorman J, Saad M, Kosseifi S, Krishnaswamy G,. Hepatitis C virus and the lung: implications for therapy. Chest 2005; 128: 2882-2892.
17. Spagnolo P, Zeuzem S, Richeldi L, du Bois RM,. The complex interrelationships between chronic lung and liver disease: a review. J Viral Hepat 2010; 17: 381-390.
18. Dicpinigaitis PV, Weiner FR,. Chronic cough associated with interferonribavirin therapy for hepatitis C. J Clinical Pharm Ther 2011; 36: 416-418.